AURA

Company Overview — What Does Aura Biosciences, Inc. Do?

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts. Aura Biosciences, Inc. (AURA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Elisabet de los Pinos and employs approximately 50 people. With a market capitalization of $430M, AURA is one of the notable companies in the Healthcare sector.

Aura Biosciences, Inc. (AURA) Stock Rating — Reduce (April 2026)

As of April 2026, Aura Biosciences, Inc. receives a Reduce rating with a composite score of 31.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AURA ranks #2,211 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aura Biosciences, Inc. ranks #256 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AURA Stock Price and 52-Week Range

Aura Biosciences, Inc. (AURA) currently trades at $6.80. The stock gained $0.02 (0.3%) in the most recent trading session. The 52-week high for AURA is $7.73, which means the stock is currently trading -12.0% from its annual peak. The 52-week low is $4.34, putting the stock 56.5% above its annual trough. Recent trading volume was 224K shares, suggesting relatively thin trading activity.

Is AURA Overvalued or Undervalued? — Valuation Analysis

Aura Biosciences, Inc. (AURA) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.11x, versus the sector average of 2.75x.

At current multiples, Aura Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aura Biosciences, Inc. Profitability — ROE, Margins, and Quality Score

Aura Biosciences, Inc. (AURA) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -74.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -60.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AURA Debt, Balance Sheet, and Financial Health

Aura Biosciences, Inc. has a debt-to-equity ratio of 24.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.15x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $48M.

AURA has a beta of 1.05, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Aura Biosciences, Inc. is 40/100, reflecting average volatility within the normal range for its sector.

Aura Biosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aura Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.76. Net income for the quarter was $-102M. Operating income came in at $-109M.

In FY 2025, Aura Biosciences, Inc. reported revenue of N/A and earnings per share (EPS) of $-1.76. Net income for the quarter was $-106M. Operating income came in at $-113M.

In Q3 2025, Aura Biosciences, Inc. reported revenue of N/A and earnings per share (EPS) of $-0.40. Net income for the quarter was $-26M. Operating income came in at $-28M.

In Q2 2025, Aura Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.47. Net income for the quarter was $-27M. Operating income came in at $-29M.

Over the past 8 quarters, Aura Biosciences, Inc. has reported varying levels of revenue. Investors analyzing AURA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AURA Dividend Yield and Income Analysis

Aura Biosciences, Inc. (AURA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AURA Momentum and Technical Analysis Profile

Aura Biosciences, Inc. (AURA) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

AURA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aura Biosciences, Inc. (AURA) ranks #256 out of 838 stocks based on the Blank Capital composite score. This places AURA in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AURA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AURA vs S&P 500 (SPY) comparison to assess how Aura Biosciences, Inc. stacks up against the broader market across all factor dimensions.

AURA Next Earnings Date

No upcoming earnings date has been announced for Aura Biosciences, Inc. (AURA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AURA? — Investment Thesis Summary

The quantitative profile for Aura Biosciences, Inc. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 17/100 indicates premium valuation.

In summary, Aura Biosciences, Inc. (AURA) earns a Reduce rating with a composite score of 31.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AURA stock.

Related Resources for AURA Investors

Explore more research and tools: AURA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AURA head-to-head with peers: AURA vs AZN, AURA vs SLGL, AURA vs VMD.